Your daily source for curated top headlines featuring the day’s biggest stories and standout moments.
Perspectify News
Filter
Massachusetts promised community-based care for those with serious mental illness. Budget cuts could undermine that.
Boston fans, it’s up to the women
Press releases
Publish your press release
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
GlobeNewswire, Inc.
-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pediatric patients with acquired hypothalamic...
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
GlobeNewswire, Inc.
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that it will...
Emerging Drugs Market to Reach $558.0 Billion by 2030, Driven by Biologics Innovation and Regulatory Support
GlobeNewswire, Inc.
Boston, May 04, 2026 (GLOBE NEWSWIRE) -- The global emerging drugs market is poised for substantial growth, expanding from $383.9 billion in 2024 to $558.0 billion by 2030, representing a compound annual growth rate (CAGR) of 6.7% over the...
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire, Inc.
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an...
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
GlobeNewswire, Inc.
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an...
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
GlobeNewswire, Inc.
CHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel...
Video Stories
Sign up for Massachusetts Healthcare Journal.
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.
Explore More
